跳至主要内容
临床试验/NCT02605538
NCT02605538撤回不适用

Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively

Karolinska University Hospital2 个研究点 分布在 1 个国家开始时间: 2015年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
2
主要终点
Positive antibody response to vaccination with Twinrix(TM) in CF patients compared to healthy volunteers

研究概览

简要总结

CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization has been complete.

详细描述

Initially, healthy volunteers will be vaccinated to be compared with patients' antibody response to hepatitis A and B vaccine.

The connected part of this study is to vaccinate children suffering from latent tuberculosis against hepatitis B and to measure whether the immunization is related to specific interferon gamma response against Mycobacterium tuberculosis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
1 Year 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CF patients not previously immunized against hepatitis A or B
  • Healthy volunteers not previously immunized against hepatitis A or B
  • Age over 1 year

排除标准

  • Previously transplanted patients
  • Previous vaccination with hepatitis vaccine
  • Known allergy against components in Twinrix (TM)

研究组 & 干预措施

Healthy volunteers

Active Comparator

Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.

干预措施: Vaccination with vaccine against hepatitis A and B (Biological)

Cystic Fibrosis

Active Comparator

Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.

干预措施: Vaccination with vaccine against hepatitis A and B (Biological)

结局指标

主要结局

Positive antibody response to vaccination with Twinrix(TM) in CF patients compared to healthy volunteers

时间窗: 6 months for vaccination

次要结局

未报告次要终点

研究者

发起方
Karolinska University Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ferenc Karpati, MD

MD, PhD

Karolinska University Hospital

研究点 (2)

Loading locations...

相似试验